Oncolytics has completed the patient enrolment in the phase II component of a phase I/II UK trial of Reolysin combined with paclitaxel/carboplatin. It is intended for patients with advanced cancers.
Interim results reported in March 2009, demonstrated that of 12 head and neck patients evaluable for clinical response, five had experienced a partial response and four had experienced stable disease ranging from two to six months, for a clinical benefit rate of 75%. Final results of the trial are expected to be released later this year.
Brad Thompson, President and CEO of Oncolytics, said: “This is an outstanding response rate in this difficult-to-treat patient population, and formed the basis of the Phase III pivotal program now being developed for Reolysin in combination with carboplatin/paclitaxel for head and neck cancer patients.”